Understand KRAS and the Quest for Anti-Cancer Drugs
Chang Woo Han, Mi Suk Jeong, Se Bok Jang
Abstract
The KRAS oncogene is mutated in approximately ~30% of human cancers, and the targeting of KRAS has long been highlighted in many studies. Nevertheless, attempts to target KRAS directly have been ineffective. This review provides an overview of the structure of KRAS and its characteristic signaling pathways. Additionally, we examine the problems associated with currently available KRAS inhibitors and discuss promising avenues for drug development.
Topics & Concepts
KRASOncogeneCancerDrug developmentCancer researchComputational biologyMedicineDrugBiologyPharmacologyInternal medicineColorectal cancerCell cycleProtein Kinase Regulation and GTPase SignalingPhosphodiesterase function and regulationPI3K/AKT/mTOR signaling in cancer